Omega-6 to Omega-3 Ratio: What Your Gut Wall Is Built From

An antibody test kit reported a resolution molecule called resolvin D1 in human blood at more than 2,000 pg/ml. Mass spectrometry, the accurate method, puts the real figure near 30 (Schebb et al., 2022). If a lab number has ever reassured you that your inflammation was under control, keep that gap in mind, because the omega-6 to omega-3 ratio of your gut wall is a better target than most of what gets tested.

Watch Your Gut Wall Is What You Fried Last Week above for the full case from The Angry Gut, written by Dr. Gurpreet Singh Padda, MD, MBA, MHP, with Ami Michelle Grimes. Here the questions are practical: what can be measured about the fat in your gut, which measurements mislead, and what actually repairs the terrain.

A lining rebuilt from last week’s groceries

Your gut is the first brain, tethered by the vagus to the second brain in your skull. Its lining turns over in days, and each new cell membrane is assembled from recently eaten fatty acids. Those membranes are not packaging. They hold the precursors for signals that start inflammation and for those that shut it down.

Tip the ratio heavily toward omega-6, the fat that dominates industrial seed oils, and the precursor pool leans toward ignition. That is metaflammation written into a single cell wall, the same engine behind the insulin resistance and aging that bring most people to regenerative medicine. It is why metabolic inflammation is the frame we work from.

The ratio is rarely a personal decision. Omega-6 oil is the cheapest fat in a commercial kitchen because the crops behind it are subsidized, and whole-fat dairy left many diets because a guideline said to remove it. The terrain gets built from policy long before it gets built from preference.

A deficit you can measure is not a deficit you can feed

The cleanest lipid finding in gastroenterology looks like an easy fix. Colonic mucus is waterproofed by a phospholipid, phosphatidylcholine. In ulcerative colitis, mucus held 745 ± 148 pmol per 100 µg protein against 2,790 in healthy controls, while Crohn’s disease sat close to normal (Braun et al., 2009).

So a delayed-release phosphatidylcholine was built to replace it, and phase 3 was halted for futility. At twelve weeks, placebo reached deep remission in 13.5% of patients, while the two drug arms reached 14.2% and 9.7% (Dignass et al., 2023).

The reason matters for every lab result you will ever be handed. A lipidomic survey of inflamed mucosa annotated 584 lipids and concluded that the colon largely makes its own phosphatidylcholine rather than importing it (Moe et al., 2025). Patients in remission looked like healthy controls. The lipid loss tracked the inflamed state, not the grocery list. Low in the tissue does not mean short in the diet.

Does a blood fat test tell you what is in the gut wall?

Mice fed three levels of EPA and DHA for five weeks raised gut tissue EPA from 0.2-0.6% at baseline to 1.6-4.3% on the richest diet, and the blood marker tracked the tissue with correlations above r > 0.91 (Gurzell et al., 2014). That is mouse data across a wide dose range, but it undercuts the claim that a blood fatty acid profile, such as an omega-3 index test, says nothing about tissue.

Now the human complication. Biopsies from 69 people with ulcerative colitis and 69 matched controls showed the expected picture in inflamed mucosa: more arachidonic acid, less EPA, a higher ratio between them. The same tissue also held more DHA, an omega-3, and less linoleic acid, the omega-6 everyone blames. Dietary intake did not differ between the groups (Pearl et al., 2013).

Inflamed tissue sorts its fats; it is not a mirror of the plate. A ratio read from blood is a useful terrain signal, and a poor verdict on its own. It belongs next to the rest of a full metabolic audit, not in place of it.

Resolvins and the measurement war

Inflammation is switched off on purpose by lipid mediators: resolvins, protectins, maresins, lipoxins. As drugs they work. Whether your own tissues make them at working concentrations is where the measurements fall apart.

The kit problem is cross-reactivity. Antibody assays pick up neighboring lipids and report the total, which is how a figure near 30 became one above 2,000. In inflamed human colon analyzed properly, the mediators built from omega-6 arachidonic acid were measurable and every EPA-derived one fell below the limit of quantitation. A 2026 method paper that validated nineteen mediators found none at all in stimulated whole blood, the sample most clinical studies draw, yet found them forming in quantity in particular immune cell arrangements (Hofstetter et al., 2026).

The cells can make these molecules. No one has shown your intestine holds them at working levels. This is a mechanism-tier position: we act on what membranes are built from, because that part can be measured and changed.

The odd-chain fat taken out of the milk

Managed bottlenose dolphins that developed a condition resembling metabolic syndrome carried the odd-chain saturated fat C17:0 at 0.3 ± 0.1%, against 1.3 ± 0.4% in dolphins with low insulin. Among dairy products tested, butter carried 423mg/100g of C17:0 and nonfat dairy products had none detectable (Venn-Watson et al., 2015).

In people, the evidence is association. Pooling 16 prospective cohorts, people with more pentadecanoic acid (C15:0) in their plasma developed type 2 diabetes less often, with a hazard ratio of 0.80 that survived adjustment for body fat (Imamura et al., 2018). Two cautions. C15:0 is the standard biomarker of dairy fat intake, so the signal may belong to the food. And the scientist proposing C15:0 as an essential fatty acid with a named deficiency syndrome founded the company that sells it, on cell, animal and cohort evidence rather than a human trial (Venn-Watson, 2024).

The practical conclusion is whole-fat dairy and fish on a plate, not a powder.

Repairing the omega-6 to omega-3 ratio in the kitchen

Repair follows the turnover. A lining rebuilt every few days responds to a steady change in raw material, meal after meal. That means moving the cooking fat away from industrial seed oil, cutting food from fryers you do not control, and bringing back marine fat and whole-fat dairy. None of it needs a supplement, and none of it depends on a test that overcounts.

The behavioral piece is where most plans fail. People keep the capsule and keep the fryer, because the capsule asks nothing of the week. The physiology will not honor that trade: membranes are built from the bulk of what arrives, not from one softgel.

For every study with its full numbers and what each shows and does not show, the Chapter 8 Deep Dive goes further, including the strongest case against this position. The wall’s protein scaffold is covered in why collagen is the wall, not the paint, and how to increase nitric oxide follows the blood supply those membranes depend on. The same fats shape the brain, as how the modern plate sets the brain on fire explains.

Frequently asked questions

What is a healthy omega-6 to omega-3 ratio?

No trial has validated a single target number for the gut. What the evidence supports is direction: a membrane built mostly from omega-6 fat carries more precursors for signals that start inflammation. The practical move is less industrial seed oil and fried food, and more marine fat, sustained long enough for a lining that turns over in days. Why inflammation accelerates aging shows where that terrain leads.

Is an omega-3 index test a good marker of gut tissue?

In mice fed a range of omega-3 doses, blood fatty acids tracked gut tissue closely, with correlations above 0.91. Human inflamed tissue is less obedient: it held more DHA and less linoleic acid than healthy tissue even though diets did not differ. Treat the result as a terrain signal alongside other markers, not a verdict. How inflammation biomarkers are read in context covers the same principle.

Is pentadecanoic acid (C15:0) an essential fatty acid?

That is a hypothesis, not an established fact. Higher blood C15:0 tracks lower type 2 diabetes across cohorts, but C15:0 is also the standard marker of dairy fat intake, and the leading proponent of essentiality founded the company selling it. The evidence is cell, animal and observational work. Whole-fat dairy is the food-first answer. Why your brain is built from fat makes a related case.

Can you get tested for resolvins?

Commercial antibody kits cross-react with neighboring lipids, which is how one resolvin measured above 2,000 pg/ml by kit and near 30 by mass spectrometry. Validated methods have not found these molecules in stimulated whole blood. A result from such a panel says little about your gut. Measuring what your diet is building is more useful. Why the same treatment heals one person and fails another explains the terrain view.

Does taking phosphatidylcholine help ulcerative colitis?

The deficit in colonic mucus is real, but a delayed-release phosphatidylcholine built to replace it was stopped in phase 3 for futility. Lipid profiling suggests the colon makes most of its own supply, so feeding more raw material does not restart a broken production line. Any treatment decision belongs with your physician. How the gut drives joint pain follows the same lining outward.

Sources

1. Braun, A., Treede, I., Gotthardt, D., Tietje, A., Zahn, A., Ruhwald, R., Schoenfeld, U., Welsch, T., Kienle, P., Erben, G., Lehmann, W.-D., Fuellekrug, J., Stremmel, W., & Ehehalt, R. (2009). Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflammatory Bowel Diseases, 15(11), 1705–1720. https://doi.org/10.1002/ibd.20993
2. Dignass, A., Stremmel, W., Horynski, M., Poyda, O., Armerding, P., Felle, T., Hoffmann, J., Klaus, J., Ludwig, D., Schmidt, C., Simon, M., Thomann, A., Zeuzem, S., & Bokemeyer, B. (2023). Modified-release phosphatidylcholine (LT-02) for ulcerative colitis: Two double-blind, randomized, placebo-controlled trials. Clinical Gastroenterology and Hepatology, 22(4), 810–820.e7. https://doi.org/10.1016/j.cgh.2023.09.031
3. Moe, O. K., Gao, Q., Geng, D., Jensen, E., Goll, R., Nestegard, O., Gundersen, M. D., Meyer, R., Florholmen, J., & Hansen, T. (2025). Marked mucosal lipid shifts in treatment refractory inflammatory bowel disease: a lipidomic study. BMC Gastroenterology, 25(1), 389. https://doi.org/10.1186/s12876-025-03944-6
4. Schebb, N. H., Kühn, H., Kahnt, A. S., Rund, K. M., O’Donnell, V. B., Flamand, N., Peters-Golden, M., Jakobsson, P.-J., Weylandt, K. H., Rohwer, N., Murphy, R. C., Geisslinger, G., FitzGerald, G. A., Hanson, J., Dahlgren, C., Alnouri, M. W., Offermanns, S., & Steinhilber, D. (2022). Formation, signaling and occurrence of specialized pro-resolving lipid mediators — what is the evidence so far? Frontiers in Pharmacology, 13, 838782. https://doi.org/10.3389/fphar.2022.838782
5. Gurzell, E. A., Wiesinger, J. A., Morkam, C., Hemmrich, S., Harris, W. S., & Fenton, J. I. (2014). Is the omega-3 index a valid marker of intestinal membrane phospholipid EPA+DHA content?. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 91(3), 87-96. https://doi.org/10.1016/j.plefa.2014.04.001
6. Pearl, D. S., Masoodi, M., Eiden, M., Brümmer, J., Gullick, D., McKeever, T. M., Whittaker, M. A., Nitch-Smith, H., Brown, J. F., Shute, J. K., Mills, G., Calder, P. C., & Trebble, T. M. (2013). Altered colonic mucosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity. Journal of Crohn’s & Colitis, 8(1), 70-79. https://doi.org/10.1016/j.crohns.2013.03.013
7. Hofstetter, R. K., Werner, M., Schädel, P., Wichmann-Costaganna, M., Fischer, K., Bruggink, V., Meyer, K. P. L., Peltner, L., Günther, K., Bachmann, V., Engelbrecht, H., Gutjahr, C., Perkowski, B., Griebel, G., Bal, N. B., Ueberschaar, N., Jordan, P. M., & Werz, O. (2026). Validated bioanalysis of oxylipins confirms specialized pro-resolving mediator formation in vitro and in vivo. Journal of Lipid Research, 67(7), 101075. https://doi.org/10.1016/j.jlr.2026.101075
8. Venn-Watson, S. K., Parry, C., Baird, M., Stevenson, S., Carlin, K., Daniels, R., Smith, C. R., Jones, R., Wells, R. S., Ridgway, S., & Jensen, E. D. (2015). Increased dietary intake of saturated fatty acid heptadecanoic acid (C17:0) associated with decreasing ferritin and alleviated metabolic syndrome in dolphins. PLoS ONE, 10(7), e0132117. https://doi.org/10.1371/journal.pone.0132117
9. Imamura, F., Fretts, A., Marklund, M., Ardisson Korat, A. V., Yang, W.-S., Lankinen, M., Qureshi, W., Helmer, C., Chen, T.-A., Wong, K., Bassett, J. K., Murphy, R., Tintle, N., Yu, C. I., Brouwer, I. A., Chien, K.-L., Frazier-Wood, A. C., Del Gobbo, L. C., Djoussé, L., … Mozaffarian, D. (2018). Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. PLoS Medicine, 15(10), e1002670. https://doi.org/10.1371/journal.pmed.1002670
10. Venn-Watson, S. (2024). The cellular stability hypothesis: Evidence of ferroptosis and accelerated aging-associated diseases as newly identified nutritional pentadecanoic acid (C15:0) deficiency syndrome. Metabolites, 14(7), 355. https://doi.org/10.3390/metabo14070355

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 8 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.